{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-028506","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.465963+00:00","generated_at":"2026-06-06T05:44:54.688368+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sana Biotechnology prices upsized $165M public offering of common stock and pre-funded warrants","bullets":["Sold 17.3M shares at $5.50 and pre-funded warrants for 12.7M shares at $5.4999 each.","Gross proceeds ~$165M; net proceeds ~$156.6M after underwriting discounts and expenses.","Underwriters granted 30-day option to purchase additional 4.5M shares.","Offering expected to close February 12, 2024; Morgan Stanley, J.P. Morgan, Goldman Sachs, BofA are joint book-runners."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-028506","json":"https://secwatch.observer/filing/0001193125-24-028506.json","markdown":"https://secwatch.observer/filing/0001193125-24-028506.md","text":"https://secwatch.observer/filing/0001193125-24-028506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000119312524028506/0001193125-24-028506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000119312524028506/d745670d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:44:54.688368+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f29f3339422521a0e270c588973d500547b352c","claim":"Sana Biotechnology, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and BofA Securities, Inc., as representatives valued at approximately $156.6 million (effective 2024-02-07).","evidence_excerpt":"On February 7, 2024, Sana Biotechnology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and BofA Securities, Inc., as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering (the “Offering”) of 17,272,728 shares of the Company’s common stock, par value $0.0001 per share, at a price to the public of $5.50 per share (the “Underwritten Shares”), and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 12,727,272 shares of the Company’s common stock at a price to the public of $5.4999 per underlying share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770121/000119312524028506/0001193125-24-028506-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and BofA Securities, Inc., as representatives"},{"label":"Value","value":"approximately $156.6 million"},{"label":"Effective","value":"2024-02-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}